4:58 PM ET
8-K
Leadership Change
Inhibikase Therapeutics Leadership Change
Inhibikase Therapeutics appointed Dr. Scott Wasserman to its Board of Directors and the Compensation Committee, effective October 19, 2026. Dr. Wasserman, currently CMO of Kailera Therapeutics and a former Amgen executive, succeeds Dennis Berman, who resigned from the Board on the same date. The change occurs as the company advances its Phase 3 IMPROVE-PAH study of IKT-001.